C4 Therapeutics, Inc. Earnings Per Share, Basic and Diluted
C4 Therapeutics, Inc. (CCCC) reported Earnings Per Share, Basic and Diluted of -$0.65 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-05
- C4 Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.65.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.32.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.51.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.51.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.82.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$5.83.
- C4 Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2019 was -$31.03.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.65 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$0.83 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.82 10-K · filed 2022-02-24 |
| 2021-09-30 | -$0.51 10-Q · filed 2021-11-10 | -$1.02 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$1.51 10-Q · filed 2021-11-10 | -$1.81 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2021-06-30 | -$0.51 10-Q · filed 2021-08-11 | -$1.00 10-Q · filed 2021-08-11 | -$1.29 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$2.53 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2021-03-31 | -$0.49 10-Q · filed 2022-05-05 | -$0.77 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$2.08 derived: net income ÷ weighted average shares · filed 2022-05-05 | -$3.36 derived: net income ÷ weighted average shares · filed 2022-05-05 |
| 2020-12-31 | -$0.28 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$1.81 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$3.56 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$5.83 10-K · filed 2022-02-24 |
| 2020-09-30 | -$17.55 10-Q · filed 2021-11-10 | -$27.01 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$36.76 10-Q · filed 2021-11-10 | -$45.21 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-06-30 | -$9.28 10-Q · filed 2021-08-11 | -$18.87 10-Q · filed 2021-08-11 | -$27.29 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$36.23 derived: net income ÷ weighted average shares · filed 2022-02-24 |
| 2020-03-31 | -$9.59 10-Q · filed 2021-05-13 | -$18.01 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$26.94 derived: net income ÷ weighted average shares · filed 2022-02-24 | |
| 2019-12-31 | -$8.40 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$17.33 derived: net income ÷ weighted average shares · filed 2022-02-24 | -$31.03 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$8.93 10-Q · filed 2020-11-12 | -$22.59 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |